Pontifax Venture Capital

Co-founders Tomer Kariv (CEO) and Ran Nussbaum (Managing Partner) lead the firm. Both are trained in law and business respectively, and they sit on the boards of multiple portfolio companies. The team’s PhD bench, including Lina Kaminski and Ohad Hammer, evaluates the scientific underpinnings of every potential investment before it reaches the partnership.

The firm invests exclusively in life sciences. Its portfolio spans three sub-sectors — Biopharma, MedTech, and Digital Health — covering therapeutics, medical devices, and health-IT platforms. Pontifax does not diversify outside of the healthcare industry, a binding constraint that distinguishes it from most Israeli venture firms.

Pontifax deploys across all stages from company formation and seed rounds through to late-stage clinical and growth-equity rounds. Its active portfolio ranges from preclinical biotechs to publicly traded pharmaceutical companies. The firm’s leadership team explicitly structures the fund to back asset-centric startups founded in-house as well as external management teams entering clinical development.

Sourcing is global, with a heavy presence in the US and Europe alongside Israel. The firm’s website lists portfolio companies in Denmark (Adcendo, Adcytherix), Belgium (Precirix), the United Kingdom (Step Pharma), and multiple US hubs. Its team’s prior roles at New York-based equity research desks and at multinational pharmaceutical companies provide a non-Israeli origination pipeline.

Eli Hurvitz (1932–2011), the former CEO and chairman of Teva Pharmaceuticals, was a co-founder and chairman of Pontifax. His pharmaceutical-operating mindset shaped a firm that manages its portfolio with hands-on board participation and strategic planning — unusual for a venture capital firm. The firm invokes his legacy as its underwriting standard when evaluating whether to pursue a company or technology.

Pontifax maintains a venture debt capability via Principal Momi Karako, who spent 16 years at Viola Credit executing more than 100 debt transactions. While the firm’s primary deployment is equity, the team’s in-house debt structuring experience gives it flexibility to use convertible structures and structured equity in mid- to late-stage financings when the capital stack warrants it.

Pontifax’s hands-on board-level approach means it typically seeks significant minority stakes with active governance roles, often as a lead or co-lead investor. The firm’s website does not advertise a passive co-investment sleeve, and its senior partners chair or sit on the boards of multiple portfolio companies, suggesting a preference for price-setting influence rather than follow-on participation in syndicates led by others.